Skip to main content
Publications
Srivastava A, Rangarajan S, Ross C, Slota C, DiBenedetti D, Cano V, Andersson S, DasMahapatra P, Bartelt-Hofer J, Afonso M. Fitusiran reaches people's with hemophilia and their caregivers' treatment expectations: qualitative semi-structured interviews of participants of ATLAS-OLE Trial (Interim analysis). Poster presented at the American Society of Hematology (ASH) Annual Meeting 2022; December 11, 2022. New Orleans, LA. [abstract] Blood. 2022 Nov 15; 140(Suppl 1):7989-90. doi: 10.1182/blood-2022-166895
Auclair D, Mansfield C, Fiala MA, Chari A, Cole CE, Kaufman JL, Orloff GJ, Siegel DS, Zonder JA, Mange B, Yesil J, Dalal M, Mikhael JR. Preferences and priorities for relapsed multiple myeloma treatments among patients and caregivers in the United States. Patient Prefer Adherence. 2022 Mar 1;2022(16):573-85. doi: 10.2147/PPA.S345906
Walters MC, Tisdale JF, Mapara MY, Krishnamurti L, Kwiatkowski JL, Aygun B, Kasow KA, Rifkin-Zenenberg S, Jaroscak J, Garbinsky D, Chirila C, Gallagher ME, Zhang X, Ho PR, Thompson AA, Kanter J. Sustained improvements in patient-reported quality of life up to 24 months post-treatment with LentiGlobin for sickle cell disease (bb1111) gene therapy. Presented at the 2021 63rd American Society of Hematology (ASH) Annual Meeting & Exposition; December 11, 2021. Atlanta, Georgia. [abstract] Blood. 2021 Nov 23; 138(Suppl 1):7. doi: 10.1182/blood-2021-146905
Germing U, Goyal RK, Yucel A, Parikh RC, Jimenez M, Sluga-O'Callaghan M, Tang D, Hughes C, Diez-Campelo M. Real-world evidence on treatment utilization in lower-risk myelodysplastic syndromes: findings from a medical record review in the United States. Poster presented at the 63rd ASH Annual Meeting and Exposition; December 11, 2021. Atlanta, GA. [abstract] Blood. 2021 Nov 23; 138(Suppl 1):4666. doi: 10.1182/blood-2021-145576
Spira AI, Chen L, Zhou X, Gnanasakthy A, Wang L, Ungar D, Curiel R, Radford JA, Kahl BS. Symptoms, health-related quality of life, and tolerability of loncastuximab tesirine in patients with relapsed or refractory diffuse large b cell lymphoma. Blood. 2020 Nov 5;136(Suppl 1):3-4. doi: 10.1182/blood-2020-139571
Cohen AD, Hari P, Htut M, Berdeja JG, Madduri D, Usmani SZ, Allred AJ, Olyslager Y, Banerjee A, Goldberg JD, Schecter JM, Jackson CC, Gries KS, Fastenau J, Deraedt W, Carrasco MJ, Akram M, Hossain F, Crawford R, Morrison R, Doward L, Jakubowiak A, Jagannath S. Patient expectations and perceptions of treatment in cartitude-1: phase 1b/2 study of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma. Poster presented at the 62nd Annual Virtual Meeting of the American Society of Hematology (ASH); December 2020. [abstract] Blood. 2020 Nov; 136(Suppl 1):13-6. doi: 10.1182/blood-2020-136383
Aletaha D, Husni ME, Merola JF, Ranza R, Bertheussen H, Lippe R, Young P, Cappelleri JC, Brown TM, Ervin C, Hsu M-A, Fallon L. Treatment mode preferences in psoriatic arthritis: a qualitative multi-country study. Patient Prefer Adherence. 2020 Jun 8;2020(14):949-61. doi: 10.2147/PPA.S242336
Taylor PC, Betteridge N, Brown TM, Woolcott J, Kivitz AJ, Zerbini C, Whalley D, Olayinka-Amao O, Chen C, Dahl P, Ponce de Leon D, Gruben D, Fallon L. Treatment mode preferences in rheumatoid arthritis: moving toward shared decision-making. Patient Prefer Adherence. 2020 Jan 20;14:119-31. doi: 10.2147/PPA.S220714
Walley D, Twiss J, Doward L, Balp MM, Brass C, Loeffler J, Lopez P, Cai J, Cryer D, Anstee Q, Sanyal A. Patient-reported symptoms and impact in nonalcoholic steatohepatitis: an evaluation of the NASH-CHECK, a novel PROM in NASH. Poster presented at the EASL: The Digital International Liver Congress; August 27, 2020. Digital. [abstract] J Hepatol. 2020 Jan; 73:S422-3. doi: 10.1016/S0168-8278(20)33053-1
Breckons M, Doward L, McSweeney L, Balp MM, Twiss J, Oluboyede Y, Vale L, Ternent L, Brass C, Sanyal A, Anstee Q. Evaluating the patient-perceived impact of non-alcoholic steatohepatitis with compensated cirrhosis. Poster presented at the EASL: The Digital International Liver Congress; August 27, 2020. digital. [abstract] J Hepatol. 2020 Jan; 73:S423. doi: 10.1016/S0168-8278(20)33053-1
Kabadi SM, Goyal RK, Nagar SP, Davis KL, Le H, Du XL, Jain P, Wang ML, Romaguera JE, Kaye JA. Overall survival, adverse events, and economic burden in Medicare-insured patients with mantle cell lymphoma receiving cancer-directed therapy. Presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):63. doi: 10.1182/blood-2019-122841
Dawson KL, Price MA, Torney PA, Gonzalez V, Sae-Hau M, Weiss E, Mange B, Mansfield C, Comenencia-Ortiz E, Masaquel A, Ravelo A. Patient-reported disease burden and age: results from a national patient advocacy survey of patients with chronic lymphocytic leukemia, diffuse large-B-cell lymphoma and follicular lymphoma. Poster presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 9, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):4778. doi: 10.1182/blood-2019-123644
Auclair D, Mansfield C, Chari A, Cole CE, Fiala MA, Kaufman JL, Orloff G, Siegel DS, Zonder JA, Mange B, Yesil J, Dalal M, Mikhael JR. Patient treatment preferences for relapsed/refractory multiple myeloma: are patients willing to trade off efficacy for tolerability? Presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition; December 3, 2018. San Diego, CA. [abstract] Blood. 2018 Nov 29; 132(Supplement 1):614. doi: 10.1182/blood-2018-99-113087
Doward L, Balp MM, Twiss J, Slota C, Cryer D, Langford A, Collen R, Agashivala N, Brass C, Anstee QM, Sanyal A. Measuring what matters to patients: the development of the NASH-CHECK, a new patient-reported outcome instrument for nonalcoholic steatohepatitis. Poster presented at the 2018 EASL International Liver Conference; April 13, 2018. Paris, France. [abstract] J Hepatol. 2018 Apr; 68(Suppl 1):S570.
Adrianzen Herrera D, Pradhan K, Snyder R, Karanth S, Janakiram M, Mantzaris I, Murthy S, Verma A, Shastri A. Myelodysplastic Syndromes (MDS) are an independent risk factor for an earlier onset of myocardial infarction and increased mortality from Cardiovascular Disease (CVD). Poster presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition; November 29, 2018. San Diego, CA. [abstract] Blood. 2018; 132(Suppl 1):3539. doi: 10.1182/blood-2018-99-115613
Doward LC, Balp MM, Stewart KE, Cryer D, Langford A, Twiss J, Agashivala N, Brass C, Anstee QM, Sanyal A. Exploring the patient perceived impact of non-alcoholic steatohepatitis. Poster presented at the 2017 EASL International Liver Conference; April 2017. Amsterdam, The Netherlands. [abstract] J Hepatol. 2017 Apr; 66(1 Supplement):S422-3. doi: 10.1016/S0168-8278(17)31208-4
Casulo C, Byrtek M, Dawson K, Zhou X, Flowers C, Farber C, Hainsworth J, Cerhan J, Link B, Friedberg J. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National LymphoCare Study. Poster presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2014. San Francisco, CA. [abstract] Blood. 2014 Dec 6; 124(21):3044. doi: 10.1182/blood.V124.21.3044.3044